Skip to content
Back
Matthew Gubin

Matthew Gubin

Parker Bridge Scholar

Biography

Matthew Gubin, PhD is a Parker Bridge Scholar and Instructor in the Department of Pathology and Immunology and in the Bursky Center for Human Immunology & Immunotherapy Programs at Washington University School of Medicine. Dr. Gubin received his B.S. degree in Biology and his Ph.D. in Immunology from the University of Missouri. Dr. Gubin then completed his postdoctoral work in Dr. Robert Schreiber’s lab at Washington University as Cancer Research Institute Irvington fellow. During his postdoc, his research focused on the use of immunogenomics to uncover the antigenic targets of T cells during cancer immunotherapy. Dr. Gubin and colleagues demonstrated in preclinical models that tumor-specific mutant antigens (neoantigens) could be rapidly identified and used as effective personalized neoantigen cancer vaccines in mice when given either alone or in combination with other immunotherapies.

Dr. Gubin then joined the faculty as an Instructor at Washington University, continuing his work in Dr. Schreiber’s lab, where he focused on the use of high dimensional analyses approaches to better understand effective cancer immunotherapy. By leveraging single cell RNA sequencing and mass cytometry by CyTOF, he and his colleagues recently identified dynamic remodeling of not only the intratumoral immune cell lymphoid compartment but also the myeloid compartment by immune checkpoint therapy, including shared and distinct changes occurring that was dependent upon which immune checkpoint therapy was used. Dr. Gubin recently accepted a position as an assistant professor in the Department of Immunology at the University of Texas MD Anderson Cancer Center, where his lab will focus on (1) developing metastatic cancer models expressing authentic (versus model) tumor-specific neoantigens, (2) high dimensional analyses of primary and metastatic tumors in both animal models and human patients, and (3) developing effective combinatorial therapies targeting neoantigens in both primary and metastatic cancer.

Get Email Updates